Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 9% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

3Q Revenues: $17.8 billion (+4%)

3Q Earnings: $4.3 billion (+27%)

YTD Revenues: $53.8 billion (+3%)

YTD Earnings: $12.7 billion (-15%)

Comments: Worldwide Pharmaceutical sales were $8.4 billion in the quarter, up 9%. Domestic sales increased 12% and international sales increased 5%. REMICADE sales were $1.8 billion in the quarter, up 11%. STELARA sales were $814 million, up 33%. SIMPONI/SIMPONI ARIA sales were $481 million, up 27%. INVEGA SUSTENNA sales were $556 million, up 21%. OLYSIO /SOVRIAD Hep C sales were down 73% in the quarter to $21 million. IMBRUVICA sales were up 90% to $349 million and XARELTO sales were $529 million, up 15%. Operational results were impacted by acquisitions (Abbott Medical Optics for $4.3 billion), divestitures (Cordis) and drop in hepatitis C sales. Worldwide Consumer sales were $3.3 billion, down 2%. Worldwide Medical Devices sales were $6.2 billion, up 1%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters